Narsoplimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Mannan-binding lectin-associated serine protease-2 (MASP2) |
| Clinical data | |
| Trade names | Yartemlea |
| Other names | OMS-721, OMS620646, narsoplimab-wuug |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Anti-inflammatory |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6340H9876N1680O1996S48 |
| Molar mass | 143109.39 g·mol−1 |
Narsoplimab, sold under the brand name Yartemlea, is a monoclonal antibody used for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. It is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody.
Narsoplimab was approved for medical use in the United States in December 2025.